UCB Governance

The Company is administered by a Board of Directors and run by an Executive Committee, whose respective functions and responsibilities are clearly defined in the Corporate Governance Charter.

UCB SA/NV has adopted the 2020 edition of the Belgian Code of Corporate Governance as its reference Code taking into account the specific international aspects of the Company. As part of these rules, UCB SA/NV, as a listed company, has adopted a Corporate Governance Charter and a Code of Conduct, including a Dealing Code.

The Corporate Governance Charter established by the Board of Directors aims at providing a comprehensive and transparent disclosure of the Company’s governance. It defines the system of checks and balances between the shareholders/investors, the Board and the management to shape an efficiently functioning company, ideally geared to produce long-term sustainable value for all the Company’s stakeholders. It will be continuously updated as required.

Articles of Association

Title Format Download
Articles of Association (ENG)
PDF
Articles of Association (FR)
PDF
Articles of Association (NL)
PDF

Special Reports of the Board

Title Format Download
Special report of the Board - 27 February 2024 (ENG)
PDF
Special report of the Board - 27 February 2024 (FR)
PDF
Special report of the Board - 27 February 2024 (NL)
PDF

Remuneration Policy 2025

Title Format Download
Remuneration Policy 2025 (ENG)
PDF
Remuneration Policy 2025 (FR)
PDF
Remuneration Policy 2025 (NL)
PDF

Related Press Releases

Corporate Governance Charter

Governance charter

UCB Dealing Code

Dealing code

Code of Conduct

Code of conduct

Board of Directors

To enhance the overall effectiveness of the Board by ensuring focus, oversight and monitoring of sensitive areas, the Board has created three specialist committees.

Composition

(Updated: April 2024)

14 Members
10 Independent Directors (71%)
8 Nationalities
6 Women (43%)
4-Year Mandate
Age Limit: 70

 
  • the Audit Committee

    The Audit Committee assists the Board in its responsibility of monitoring the management of UCB and the UCB Group as a whole.
     

    3 members  (67% independent):

    • Rodolfo J. Savitzky (Chair & Independent Director)
    • Maëlys Castella (Independent Director)
    • Cédric van Rijckevorsel (Director)
  • the Governance, Nomination and Compensation Committee (GNCC)

    The Governance, Remuneration and Nomination Committee (GNCC) ensures that the appointment and re-election process is organized objectively and professionally and proposes the remuneration policy for non-executive Directors and executive managers.

     

    5 members  (80% independent):

    • Kay Davies (Chair & Independent Director)
    • Charles-Antoine Janssen (Director)
    • Pierre Gurdjian (Independent Director)
    • Nefertiti Greene (Independent Director)
    • Ulf Wiinberg (Independent Director)
  • the Scientific Committee

    The Scientific Committee assists the Board when reviewing the quality of UCB’s R&D science and its competitive standing. It assesses the strategy proposed by UCB’s management in R&D matters and communicates its recommendations to the Board.

     

    3 members  (100% independent):

    • Kay Davies (Independent Director)
    • Susan Gasser (Independent Director)
    • Dolca Thomas (Independent Director)

Jonathan Peacock

Independent Director
Chair of the Board
 

First appointed in 2021
End of term in 2025

BIO - J. Peacock

Charles-Antoine Janssen

Director
Vice-chair of the Board
Member of the GNCC

First appointed in 2012
End of term in 2028

BIO - CA Janssen

Jean-Christophe Tellier

Executive Director



First appointed in 2014
End of term in 2026

BIO - JC Tellier

Jan Berger

Independent Director



First appointed in 2019
End of term in 2027

BIO - J. Berger

Maëlys Castella

Independent Director
Member of the Audit Committee


First appointed in 2023
End of term in 2027

BIO - M. Castella

Kay Davies

Independent Director
Member of the Scientific Committee
Chair of the GNCC

First appointed in 2014
End of term in 2026

BIO - K. Davies

Pierre Gurdjian

Independent Director
Member of the GNCC

 


First appointed in 2016
End of term in 2028

BIO - P. Gurdjian

Cédric van Rijckevorsel

Director
Member of the Audit Committee

First appointed in 2014
End of term in 2026

BIO - C. van Rijckevorsel

Cyril Janssen

Director



First appointed in 2015
End of term in 2027

BIO - C. Janssen

Ulf Wiinberg

Independent Director
Member of the GNCC
 

First appointed in 2016
End of term in 2028

BIO - U. Wiinberg

Nefertiti Greene

Independent Director
Member of the GNCC

 

First appointed in 2024
End of term in 2028

BIO - N. Greene

Rodolfo Savitzky

Independent Director
Chair of the Audit Committee

 

First appointed in 2024
End of term in 2028

BIO - R. Savitzky

Dolca Thomas

Independent Director
Member of the Scientific Committee

 

First appointed in 2024
End of term in 2028

BIO - D. Thomas

Stef Heylen, MD

Director



First appointed in 2025
End of term in 2029

BIO - S. Heylen
  • Honorary directors
    • Karel Boone, Honorary Chair
    • Evelyn du Monceau, Honorary Chair
    • Mark Eyskens, Honorary Chair
    • Georges Jacobs de Hagen, Honorary Chair
    • Daniel Janssen, Honorary Deputy Chair
    • Gerhard Mayr, Honorary Chair
    • Prince Lorenz of Belgium
    • Alan Blinken
    • Alice Dautry
    • Arnoud de Pret
    • Roch Doliveux
    • Peter Fellner
    • Guy Keutgen
    • Jean-Pierre Kinet
    • Tom McKillop
    • Gaëtan van de Werve
    • Jean-Louis Vanherweghem
    • Bridget van Rijckevorsel
    • Norman J. Ornstein
  • Honorary chairmen of the Executive Committee
    • Roch Doliveux
    • Georges Jacobs de Hagen
    • Daniel Janssen

Executive Committee

We have adapted an organizational structure on four pillars around which we create value for each patient, centered by our focus and integrated across functional teams around different patient populations.

 

Composition

(Updated: July 2024)

8 members
5 nationalities
4 women (50%)
 

 

Jean-Christophe Tellier

Chief Executive Officer &
Chairman of the Executive Committee

Joined UCB in 2011
Appointed CEO in 2015

 
BIO - JC Tellier

Emmanuel Caeymaex

Executive Vice President
Chief Commercial Officer
  

Joined UCB in 1994
Appointed in 2015

BIO - E. Caeymaex

Sandrine Dufour

Executive Vice President
Chief Financial Officer
  

Joined UCB in July 2020
Appointed in July 2020

 
BIO - S. Dufour

Jean Luc Fleurial

Executive Vice President
Chief Human Resources Officer
  

Joined UCB in 2017
Appointed in 2017

 
BIO - JL Fleurial

Fiona du Monceau

Executive Vice President
Patient Evidence
  

Joined UCB in 2024
Appointed in 2024

 
BIO - F. du Monceau

Kirsten Lund-Jurgensen

Executive Vice President
Patient Supply
  

Joined UCB in 2019
Appointed in 2019

BIO - K. Lund-Jurgensen

Alistair Henry

Executive Vice President &
Chief Scientific Officer
  

Joined UCB in 2004
Appointed in 2024

 
BIO - A. Henry

Denelle J. Waynick Johnson

Executive Vice President &
General Counsel
  

Joined UCB in 2023
Appointed in 2023

 
BIO - D. J. Waynick Johnson

Shareholders and Shareholder Meetings

Find out about UCB shareholders, their transparency notifications and our shareholder meetings on the dedicated webpage.

 

Contact UCB IR Team

investor-relations@ucb.com or a specific team member:

Antje Witte, Head of Investor Relations
Tel: +32 2 559 9414
E-mail: Antje.Witte@ucb.com



Sahar Yazdian, Investor Relations Lead

Tel: +32 2 559 9137
E-mail: Sahar.Yazdian@ucb.com

UCB IR App